Friday, July 31, 2026

Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track

 Solid first quarter performance broadly in line with guidance, underpinned by resilient demand across core in-line brands

Commercial execution and late-stage pipeline investments on schedule, including first approval for ORZEYFULTM (oveporexton) in China, setting the foundation for next wave of medicines

No change to FY2026 full-year forecast and management guidance

 


(BUSINESS WIRE) -- Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first quarter of fiscal year 2026 (April 1, 2026 to June 30, 2026), marking a period of disciplined execution and operational momentum. Takeda leveraged the resilient performance of its core in-line portfolio to support its long-term strategy, advancing commercial launch preparations and driving critical R&D pipeline milestones. With a clear operational trajectory established in the first quarter and under a new operating model, Takeda remains on track to deliver its strategic and financial commitments for the fiscal year.


FY2026 First Quarter Highlights


Revenue increased by +10.2% versus the prior-year period on an actual exchange rate (AER) basis and decreased by -0.5% on a Constant Exchange Rate (CER) basis as the negative impact of the loss of exclusivity of VYVANSE® was largely offset by growth from core in-line brands.


Core Operating Profit increased by +11.5% on an AER basis and decreased by -0.5% on a CER basis, reflecting continued growth investments supported by the transformation program.


Reported Operating Profit increased by +9.1% on an AER basis.


Core EPS increased by +1.5% at AER and decreased by -11.8% at CER, while Reported EPS decreased by -9.8% YoY.


Adjusted Free Cash Flow amounted to JPY 68.6 billion.


Launch preparations for key late-stage pipeline assets (ORZEYFUL, rusfertide and zasocitinib) are progressing on schedule, with the first approval for ORZEYFUL achieved in China.


FY2026 full-year outlook remains unchanged.


A Capital Markets Day will be held on December 11, 2026, in Tokyo, Japan.


Takeda President and Chief Executive Officer, Julie Kim, commented:

“Our solid performance this quarter marks a good start to the fiscal year and keeps us on track to achieve our full-year targets.


“This quarter’s results reflect our unwavering commitment to financial discipline and the progressing execution of our enterprise transformation. The efficiencies unlocked by this ongoing program are directly fueling our highest priorities in Horizon One in our two-horizon growth strategy: the successful launch of three medicines that have the potential to be blockbuster brands, the advancement of our late-stage pipeline, the enduring resilience of our core in-line portfolio and new capabilities and efficiencies gained through transformation. We look forward to sharing the detailed strategic roadmap for these two growth horizons at our Capital Markets Day in December.”


Takeda Chief Financial Officer, Milano Furuta, commented:

“Our first-quarter performance is tracking consistently with management guidance, with the resilience of our core in-line brands largely offsetting our mature portfolio decline, and OPEX savings through the transformation program being strategically reinvested to fund future growth opportunities. Our full-year forecast and guidance remain unchanged.”


FINANCIAL HIGHLIGHTS for First Quarter Results ended June 30, 2026


Pipeline Progress Building the Foundation for Future Growth

Takeda’s next-generation growth engine is anchored by three, high-potential, late-stage pipeline assets expected to obtain regulatory approvals in the U.S. and other key regions in the coming year. While this represents a pivotal period of strategic investment and commercial launch execution, Takeda is positioned to deliver tangible milestones over the next 12 to 24 months. By establishing a track record of launch excellence today, Takeda is securing the foundation that will underpin the Company’s sustained, long-term growth and meaningful impact for patients globally.


ORZEYFUL


An orexin receptor agonist with a first-in-class mechanism of action, designed to address the orexin deficiency that causes narcolepsy type 1 (NT1).


The first approval of oveporexton was recently granted in China under the brand name ORZEYFUL.


New drug applications are currently under review in the United States and Japan.


Preparations for the expected launches in the U.S., Japan and China in the second half of the year are well underway.


At SLEEP 2026, Takeda presented Phase 3 clinical trial results for ORZEYFUL demonstrating improvements in daily functioning, cognition and nighttime sleep in patients with narcolepsy type 1.


Rusfertide


A potential first-in-class hepcidin mimetic for the treatment of adults with the blood cancer polycythemia vera (PV).


Demonstrated significant improvements in hematocrit control and phlebotomy reduction for patients with PV in a Phase 3 clinical trial.


Granted Priority Review by the U.S. FDA, Takeda is prepared for a commercial U.S. launch expected in the second half of 2026.


Zasocitinib


A next generation, highly selective and potent TYK2 inhibitor that has demonstrated rapid, durable skin clearance in a convenient once-daily oral pill with no fasting restrictions.


Achieved positive topline results across the primary endpoint and all key secondary endpoints in a head-to-head Phase 3 clinical trial against deucravacitinib.


Achieved consistent, high rates of skin clearance across the body, including hard-to-treat and high-impact sites in Phase 3 psoriasis studies.


Takeda is making the necessary investments with a view toward regulatory submissions in 2026 and a commercial launch anticipated in the first half of 2027.


Capital Allocation and Shareholder Returns

Takeda maintains a disciplined capital allocation framework that prioritizes investments in new launches and R&D innovation with the goal of driving growth and enabling the company to deliver returns to shareholders under its progressive dividend policy. The annual dividend forecast for FY2026 is JPY 204 per share.


Additional Information Regarding FY2026 First Quarter Results

Takeda will host a conference call for investors and analysts on Thursday, July 30, 2026, at 19:00 Japan Time / 6:00 U.S. Eastern Time to discuss its FY2026 first quarter results.


A live webcast of the conference call and the presentation materials will be available in the Investor Relations section of Takeda’s website (www.takeda.com/investors). The presentation materials include details on Takeda’s FY2026 first quarter results, business progress and pipeline updates, as well as definitions of non-IFRS measures.


Note: ORZEYFUL is the proprietary name approved in China for oveporexton. References to ORZEYFUL are provided for consistency only and should not be interpreted as indicating regulatory approval or acceptance of the proprietary name in jurisdictions where the product remains under regulatory review 


About Takeda

Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit https://www.takeda.com.


Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.


The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.


The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.


Forward-Looking Statements


This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including drug pricing, tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.


Financial information and Non-IFRS Measures


Takeda’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”).


This press release and materials distributed in connection with this press release include certain financial measures not presented in accordance with IFRS, such as Core Revenue, Core Operating Profit, Core Net Profit for the year attributable to owners of the Company, Core EPS, Constant Exchange Rate (“CER”) change, Net Debt, Adjusted Net Debt, EBITDA, Adjusted EBITDA, Free Cash Flow and Adjusted Free Cash Flow. Takeda’s management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this press release. These non-IFRS measures exclude certain income, cost and cash flow items which are included in, or are calculated differently from, the most closely comparable measures presented in accordance with IFRS. Takeda’s non-IFRS measures are not prepared in accordance with IFRS and such non-IFRS measures should be considered a supplement to, and not a substitute for, measures prepared in accordance with IFRS (which we sometimes refer to as “reported” measures). Investors are encouraged to review the definitions and reconciliations of non-IFRS measures to their most directly comparable IFRS measures, which are in the Financial Appendix appearing at the end of our FY2026 Q1 investor presentation (available at www.takeda.com/investors).


Medical Information


This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260727883646/en/



Permalink

https://www.aetoswire.com/en/news/3007202656529


Contacts

Investor Relations

Christopher O’Reilly

Takeda.ir.contact@takeda.com

Media Relations

Shoko Honda

toiawase_kouhou@takeda.co.jp (Tokyo)

media_relations@takeda.com (Boston)


 

Mary Kay Releases 2026 Sustainability Report Highlighting Transformative Progress Across Social, Economic, and Environmental Impact Globally

 Beauty Leader Ranked #8 on Forbes’ 2026 Best Brands For Social Impact List


(BUSINESS WIRE) -- Mary Kay Inc., a leading global beauty company committed to sustainability and women’s empowerment, today released its 2026 Sustainability Report, outlining progress toward its 2030 goals and celebrating the 2025 and latest achievements that continue to drive positive change globally.


The annual report highlights Mary Kay’s decades-long dedication to social, economic, and environmental sustainability - core pillars central to its business strategy and its purpose-driven legacy rooted in the company’s mission of “enriching women’s lives” around the world.


“Mary Kay’s commitment to enriching women’s lives continues to guide how we operate, innovate, and create sustainable impact across the beauty industry while advancing women’s entrepreneurship for all generations around the world,” said Ryan Rogers, Chief Executive Officer of Mary Kay. “This report reflects the measurable progress we are making against our 2030 commitments and the transformative social, economic, and environmental change we are helping create for people, communities, and the planet.”


From biodiversity and product stewardship to women’s empowerment and digital innovation, Mary Kay continues to embed sustainability throughout its business, advancing positive impact around the world. Below are key 2025 highlights:


ENVIRONMENTAL


Responsible Packaging: Mary Kay reaffirmed its commitments to reducing plastic intensity, increase post-consumer recycled content (PCR), and increase recycle-ready/recyclable packaging1. For example, the bottle of Mary Kay TimeWise® Targeted-Action® Toning Lotion contains 94% post-consumer recycled (PCR) content2.


Resource Conservation: Mary Kay prioritized the use of sustainable paper sources for product cartons and paper inserts, distribution cases, and shipping boxes - 100% of Mary Kay’s product paper cartons are recycle-ready in the Americas and in Europe. Mary Kay has a goal of 90% of product cartons certified globally by 2030 and is supporting the Forest Stewardship Council® (FSC®), an international non-governmental organization that promotes environmentally appropriate, socially beneficial, and economically viable management of the world’s forests.


Impact Memberships for Sustainable Sourcing: Mary Kay has been supporting global organizations such as the Global Shea Alliance since 2023 and the Roundtable on Sustainable Palm Oil since 2014.


Water Management: 100% of the water used at the global Richard R. Rogers Manufacturing/R&D Center (R3) in Texas is treated and recycled back into the local watershed.


Impact Partnerships: Mary Kay celebrated its 39-year partnership with The Nature Conservancy representing more than 100 conservation projects supported in the U.S. and globally.


SOCIAL


Pink Changing Lives®: More than $230 million has been donated in monetary and in-kind donations by Mary Kay Inc. and its four Company-sponsored foundations globally since 19963 - including through funding cancer research, helping survivors of domestic violence, or creating opportunities for women and their families around the world.


Women’s Empowerment: Globally, more than 600,000 women have been positively impacted through Mary Kay‑led and supported empowerment initiatives spanning entrepreneurship, education, and community development. In 2025, Mary Kay continued its long‑standing partnership with the City of Lewisville, Lewisville Independent School District Education Foundation and INCubatoredu, supporting high school students as part of a yearlong entrepreneurial curriculum designed to expose them to real world business principles and creation resulting in a final pitch event to compete for seed funding.


Future of STEM: 51 grants and more than $234,000 awarded to young women from 17 countries pursuing STEM careers; 10 grants awarded to female students through the Madam C.J. Walker Scholarships with the Society of Cosmetic Chemists sponsored by Mary Kay as of 2025. More than 300 young women were exposed to STEM career pathways through immersive experiences at the global Richard R. Rogers Manufacturing/R&D Center (R3).


Impact Partnerships: Mary Kay served as a Special Award Organization (SAO) at the International Science and Engineering Fair in 2024 and 2025 awarding a total of 18 grants to next-gen innovators in diverse STEM categories.


ECONOMIC


Women-Powered: 63% of the Executive Team, 64% of Research and Development Scientists, 79% of the Global Brand and Global Creative Team, 63% of our Global Workforce, and 60% of Leadership Positions in Mary Kay’s Top 10 Markets are held by women4.


Global Footprint: Mary Kay celebrated its presence in 40 markets around the world with a series of milestone anniversaries in 2025: Argentina (45 years); China (30); Portugal (30); Kazakhstan (25); Malaysia (25); Philippines (25); Slovakia (25); Armenia (15); Colombia (10).


Digital Transformation: At the core of Mary Kay’s digital transformation is a cloud-first strategy and full-scale modernization of the Company’s technology infrastructure, including the migration of over 95% of custom applications to integrated SaaS5 in support of critical operations, from e-commerce to supply chain and ERP6 systems. A major 2025 milestone is the launch of the My Shop platform in Germany and in the United States. My Shop empowers Independent Beauty Consultants with personalized online storefronts, fully integrated with Mary Kay’s broader e-commerce, payment, and fulfillment systems, meeting consumers’ needs of seamless, on-demand, and convenient buying journeys. My Shop is being rolled out globally in 2026 and beyond.


Quality Certified: Achieved ISO 22716, the global gold standard for Good Manufacturing Practices (GMP) in the cosmetics industry at Mary Kay’s global Richard R. Rogers Manufacturing/R&D Center (R3) in Lewisville, Texas.


Advocacy: Engaged in 100+ trade associations globally on a range of policy issues from direct selling and entrepreneurship to personal care and supply chain and logistics.


Topping The Charts: In 2025 Mary Kay earned 25 corporate awards spanning corporate excellence, the direct selling industry, social impact, sustainability, and science and innovation.


Latest Top-tier Global Recognition Includes:


Mary Kay was named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World7 by Euromonitor International for four consecutive years (2023-2026).


Mary Kay ranked #2 on Forbes 2026 Best Customer Service list moving up from #93 in 20258. Mary Kay is the only Beauty brand in the Top 15 and the only direct-selling company in the Top 50.


Mary Kay ranked #8 out of 5,500 brands on Forbes’s 2026 Best Brands for Social Impact9 moving up from stellar #9 achieved in 2025. Mary Kay is the only beauty brand in the Top 15 and the only direct selling company on the list.


Mary Kay ranked #19 in the Women’s Wear Daily Beauty Inc.’s 2025 Top 100 Beauty Companies released in 2026.


Mary Kay’s 2026 Sustainability Report is aligned with the United Nations Sustainable Development Goals (SDGs) and serves as a benchmark for stakeholders and partners seeking to drive collective impact.


To view the full report, visit here.


About Mary Kay


One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in 40 markets. For over 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com. Find us on Facebook, Instagram, and LinkedIn.


1 Recyclable only where facilities exist.

2 Percentage of post-consumer recycled content may vary based on availability and geographic region.

3 While the Company has provided philanthropic support to charitable causes for many decades, official documentation began in 1996 with the founding of the Mary Kay Ash Foundation® (U.S.).

4 Women Representation and Leadership at Mary Kay (May 2026).

5 SaaS platform solution: a cloud-based software model that allows users to access applications remotely via the internet.

6 Global ERP Solutions: specialized resource planning systems designed to manage multinational operations across multiple countries, regions, currencies, and languages, business processes such as finance, HR, sales, and inventory management into a single platform, enabling seamless data flow and real-time analytics.

7 “Source Euromonitor International Limited; Beauty and Personal Care 2026 Edition, Value Sales at RSP, 2025 Data”

8 Alan Schwarz (October 14, 2025). Forbes - Best Customer Service 2026. https://www.forbes.com/lists/best-customer-service/

9 Alan Schwarz (March 17, 2026). Forbes - Best Brands For Social Impact 2026. https://www.forbes.com/lists/best-brands-social-impact/


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260730240667/en/



Permalink

https://www.aetoswire.com/en/news/3007202656535


Contacts

Mary Kay Inc. Corporate Communications

newsroom.marykay.com

972.687.5332 or media@mkcorp.com


 

AB InBev Reports Second Quarter 2026 Results

BRUSSELS - Thursday, 30. July 2026



Solid top- and bottom-line performance: Revenue up by 5.6%, Beer volume growth of 1.1% and a 23.4% Underlying EPS increase


(BUSINESS WIRE) -- Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD):


Regulated information1


“Cheers to beer – our performance this quarter reflects the strength of the beer category and the consistent execution of our strategy. Through investment in our megabrands and mega platforms, innovation and offering more choices across more occasions, we are strengthening the cultural relevance of our brands with consumers. Thank you to our colleagues for their commitment and disciplined execution, which position us well to continue our momentum.” – Michel Doukeris, CEO, AB InBev


Revenue


+5.6%


Revenue increased by 5.6% in 2Q26 with revenue per hl growth of 4.2% and by 5.7% in HY26 with revenue per hl growth of 4.3%.


 


Reported revenue increased by 11.0% in 2Q26 to 16 660 million USD and by 11.5% in HY26 to 31 927 million USD, positively impacted by currency translation.


 


6.2% increase in combined revenues of megabrands in 2Q26, led by Corona, which grew by 17% outside of its home market.


27% increase in revenue of no-alcohol beer in 2Q26.


44% increase in revenue of Beyond Beer in 2Q26.


50% increase in Gross Merchandise Value (GMV) from sales of third-party products through BEES Marketplace to reach 1.2 billion USD in 2Q26.


 


Volumes

+0.9%


Volumes increased by 0.9% in 2Q26, with beer volumes up by 1.1% and non-beer volumes down by 1.1%.


Volumes increased by 0.8% in HY26, with beer volumes up by 1.2% and non-beer volumes down by 1.5%.


 


Normalized EBITDA


+5.8%


Normalized EBITDA increased by 5.8% to 5 938 million USD in 2Q26, with a margin expansion of 4bps to 35.6%.


Normalized EBITDA increased by 5.6% to 11 375 million USD in HY26, with a margin contraction of 5bps to 35.6%.


 


Underlying Profit


2 390 million USD


Underlying Profit was 2 390 million USD in 2Q26 compared to 1 950 million USD in 2Q25 and was 4 314 million USD in HY26 compared to 3 556 million USD in HY25.


Reported profit attributable to equity holders of AB InBev was 3 751 million USD in 2Q26 compared to 1 676 million USD in 2Q25, and was 6 314 million in HY26 compared to 3 824 million in HY25, with HY25, 2Q26 and HY26 positively impacted by non-underlying items.


 


Underlying EPS


1.21 USD


Underlying EPS increased by 23.4% to 1.21 USD in 2Q26, compared to 0.98 USD in 2Q25, and increased by 22.1% to 2.18 USD in HY26, compared to 1.79 USD in HY25.


On a constant currency basis, Underlying EPS increased by 12.9% in 2Q26 and by 11.0% in HY26.


Net Debt to EBITDA


2.86x


Net debt to normalized EBITDA ratio was 2.86x at 30 June 2026 compared to 3.27x at 30 June 2025 and 2.87x at 31 December 25.


The 2026 Half Year Financial Report is available on our website at www.ab-inbev.com.


1The enclosed information constitutes regulated information as defined in the Belgian Royal Decree of 14 November 2007 regarding the duties of issuers of financial instruments which have been admitted for trading on a regulated market. For important disclaimers and notes on the basis of preparation, please refer to page 15.

Management comments


Consistent and compounding growth with beer volume up by 1.1% and a 23.4% Underlying EPS increase


The momentum of our business continued in 2Q26, with broad-based volume growth and a 23.4% increase in Underlying EPS. While the consumer environment remains dynamic, consistent execution of our strategy and investment in our megabrands and mega platforms enabled solid top- and bottom-line results. We strengthened our portfolio brand power and estimate that we gained market share across our footprint, maintaining or gaining share in 70% of our markets.


Revenue increased by 5.6%, with total volume growth of 0.9% and a revenue per hl increase of 4.2%, driven by revenue management and positive mix from premiumization and Beyond Beer. Beer volumes grew by 1.1%, with record high second quarter volumes in Mexico, Colombia, and Ecuador. Beer volumes in Brazil returned to growth, and in the US we delivered continued top-line growth and market share gains in both beer and Beyond Beer.


EBITDA increased by 5.8% with flattish margins as overhead management enabled increased sales and marketing investment and offset transactional FX headwinds. Free cash flow increased by 2.5 billion USD versus HY25 to 3.9 billion USD, driven by disciplined execution and the continued optimization of our business.


Key highlights from the quarter included: global megabrand momentum, with Corona, Stella Artois and Michelob Ultra growing revenue by 17%, 19% and 21%, respectively, outside of their home markets; successful activation of the FIFA World Cup across our markets, supporting growth of Michelob Ultra in the US and providing a platform to expand the brand across key markets in Latin America; no-alcohol beer revenue growth of 27%, Beyond Beer revenue growth of 44%, and BEES Marketplace GMV growth of 50% to 1.2 billion USD.


Progressing our strategic priorities


We are executing on three key strategic pillars to deliver consistent growth and long-term value creation.


(1) Lead and grow the category:


We strengthened our portfolio brand power and estimate that we gained or maintained share in 70% of our markets in 2Q26.


(2) Digitize and monetize our ecosystem:


BEES Marketplace GMV increased by 50% versus 2Q25 to 1.2 billion USD from third-party products. Overall BEES GMV increased by 16% versus 2Q25 to 15.0 billion USD.


(3) Optimize our business:


We continued to strengthen our balance sheet, with net debt to EBITDA improving to 2.86x as of 30 June 2026 from 3.27x as of 30 June 2025.


(1) Lead and grow the category


Investment in our megabrands and mega platforms continued to build portfolio brand power, with sales and marketing investment reaching 4.1 billion USD in HY26, up 9% versus HY25. According to the Kantar BrandZ 2026 report, our portfolio holds 8 of the top 10 most valuable beer brands in the world, with Corona and Budweiser ranked #1 and #2, respectively. Our mega platforms strengthened the cultural relevance of our brands during some of the world’s largest moments of celebration, including the Winter Olympics, Roland Garros, Wimbledon and the FIFA World Cup. Across these occasions, our portfolio achieved the #1 share of digital engagement and generated 850 million consumer engagements on social media. Our marketing capabilities were recognized as we were named the Cannes Lions 2026 Creative Marketer of the Year, making us the only company in history to receive this recognition three times.


We continued to execute on our category expansion levers and estimate that the number of legal drinking age consumers purchasing our portfolio increased in HY26 with gains in Beyond Beer and Balanced Choices.


Core Superiority: Revenue of our mainstream portfolio increased by 2.7% in 2Q26, driven by double-digit growth in Colombia and high-single digit growth in Peru and Ecuador.


Premiumization: Our above core beer portfolio delivered a 6.9% revenue increase in 2Q26, led by Corona, Stella Artois and Michelob Ultra, which grew revenue by 17%, 19% and 21%, respectively, outside of their home markets. Corona led the premiumization of our portfolio globally, delivering double-digit volume growth in 37 markets. Michelob Ultra expanded across Latin America in 2Q26, with 40% of its volume growth coming from markets outside of the US.


Balanced Choices: Our portfolio of low carb, low calorie, sugar free, gluten free and no-alcohol beer brands delivered a revenue increase of 13% in 2Q26. Our no-alcohol beer portfolio led performance, with revenue up by 27% and estimated share gains strengthening our leadership in no-alcohol beer by value, according to Nielsen.


Beyond Beer: Growth of our portfolio accelerated, increasing revenue by 44% in 2Q26. Performance was led by the expansion of Flying Fish globally and by Cutwater in the US, which increased revenue by triple-digits and was the 2nd largest contributor by brand to our overall revenue growth in 2Q26.


(2) Digitize and monetize our ecosystem


Digitizing our relationships with more than 6 million customers globally: As of 30 June 2026, BEES was live in 30 markets with 72% of our revenues captured through B2B digital platforms. In 2Q26, BEES captured 15.0 billion USD in GMV, up 16% versus 2Q25.


Monetizing our route-to-market; delivering more than 1 billion USD in quarterly GMV: BEES Marketplace GMV increased by 50% versus 2Q25 to approximately 1.2 billion USD from third-party products.


Leading the way in DTC solutions: Our digital DTC megabrands, Zé Delivery, TaDa Delivery and PerfectDraft, served 13 million active consumers and generated 165 million USD in revenue, 12% growth versus 2Q25. Sales of third-party products through our DTC marketplace reached 50 million USD in GMV, a 63% increase versus 2Q25.


(3) Optimize our business


Maximizing value creation: Continued optimization of our business and operating leverage through the P&L drove EBIT growth of 8.0% and a free cash flow increase of 2.5 billion USD versus HY25. We strengthened our balance sheet, with net debt to EBITDA improving to 2.86x from 3.27x as of 30 June 2025. As of 24 July 2026, we completed 1.9 billion USD of our 6 billion USD share buyback program announced on 30 October 2025.


Advancing our sustainability priorities: Our water use efficiency ratio improved to 2.3 hl per hl in HY26 versus 2.4 hl per hl in HY25. Our average energy efficiency globally improved to 81.6 MJ/hl in HY26 versus 84.8 MJ/hl in HY25. Our absolute Scopes 1 and 2 emissions were 1.55 million metric tons of CO2e in HY26, a 0.8% decrease compared to HY25.


Continued momentum and reliable compounding growth


In HY26, our business delivered 5.7% revenue growth, 5.6% EBITDA growth and a 22.1% increase in Underlying EPS, driven by beer volume growth, revenue and cost management capabilities, and positive mix. We strengthened our portfolio brand power through investment in our megabrands and mega platforms, scaling our innovations and providing more choices across more occasions. Performance across our megabrands, Balanced Choices, Beyond Beer and BEES Marketplace reflects the strength of our portfolio and the consistent execution of our strategy.


The continued momentum of our business, disciplined execution by our teams and the strength of the beer category reinforce our confidence in our ability to deliver our FY26 outlook and create a future with more cheers.


2026 Outlook


(i) Overall Performance: We expect our EBITDA to grow in line with our medium-term outlook of between 4-8%. The outlook for FY26 reflects our current assessment of inflation and other macroeconomic conditions.


(ii) Net Finance Costs: Net pension interest expenses and accretion expenses are expected to be in the range of 190 to 220 million USD per quarter, depending on currency and interest rate fluctuations. We expect the average gross debt coupon in FY26 to be approximately 4%.


(iii) Effective Tax Rate (ETR): We expect the normalized ETR in FY26 to be in the range of 26% to 28%. The ETR outlook does not consider the impact of potential future changes in legislation.


(iv) Net Capital Expenditure: We expect net capital expenditure of between 3.5 and 4.0 billion USD in FY26.


Figure 1. Consolidated performance


in USD Mio, except EPS in USD per share and Volumes in thousand hls


 

2Q25


 

2Q26


 

Organic


 

growth


Volumes


 

143 347


 


 

144 003


 


 

0.9


%


Beer


 

125 620


 


 

126 945


 


 

1.1


%


Non-Beer


 

17 727


 


 

17 058


 


 

(1.1


)%


Revenue


 

15 004


 


 

16 660


 


 

5.6


%


Gross profit


 

8 446


 


 

9 579


 


 

7.5


%


Gross margin


 

56.3


%


 

57.5


%


 

99bps


Normalized EBITDA


 

5 301


 


 

5 938


 


 

5.8


%


Normalized EBITDA margin


 

35.3


%


 

35.6


%


 

4bps


Normalized EBIT


 

4 013


 


 

4 604


 


 

8.0


%


Normalized EBIT margin


 

26.7


%


 

27.6


%


 

58bps


 


   

Profit attributable to equity holders of AB InBev


 

1 676


 


 

3 751


 


   

Underlying Profit


 

1 950


 


 

2 390


 


   

 


   

Basic EPS


 

0.84


 


 

1.90


 


   

Underlying EPS


 

0.98


 


 

1.21


 


 

 


 

HY25


 

HY26


 

Organic


 

growth


Volumes


 

279 615


 


 

280 412


 


 

0.8


%


Beer


 

243 005


 


 

245 426


 


 

1.2


%


Non-Beer


 

36 611


 


 

34 987


 


 

(1.5


)%


Revenue


 

28 632


 


 

31 927


 


 

5.7


%


Gross profit


 

16 029


 


 

18 225


 


 

7.4


%


Gross margin


 

56.0


%


 

57.1


%


 

88bps


Normalized EBITDA


 

10 156


 


 

11 375


 


 

5.6


%


Normalized EBITDA margin


 

35.5


%


 

35.6


%


 

(5)bps


Normalized EBIT


 

7 601


 


 

8 677


 


 

7.6


%


Normalized EBIT margin


 

26.5


%


 

27.2


%


 

46bps


 


   

Profit attributable to equity holders of AB InBev


 

3 824


 


 

6 314


 


   

Underlying Profit


 

3 556


 


 

4 314


 


   

 


   

Basic EPS


 

1.92


 


 

3.20


 


   

Underlying EPS


 

1.79


 


 

2.18


 


 

 


Figure 2. Volumes


in thousand hls


 

2Q25


 

Scope


 

Organic


 

2Q26


 

Organic growth


 

growth


 

Total


 

Beer


North America


 

22 376


 

218


 


 

(164


)


 

22 430


 

(0.7


)%


 

(0.8


)%


Middle Americas


 

38 822


 

(634


)


 

1 806


 


 

39 994


 

4.7


%


 

4.8


%


South America


 

34 199


 

-


 


 

466


 


 

34 665


 

1.4


%


 

3.9


%


EMEA


 

24 172


 

(135


)


 

201


 


 

24 239


 

0.8


%


 

0.9


%


Asia Pacific


 

23 716


 

(21


)


 

(1 109


)


 

22 586


 

(4.7


)%


 

(4.7


)%


Global Export and Holding Companies


 

62


 

14


 


 

12


 


 

89


 

16.3


%


 

16.3


%


AB InBev Worldwide


 

143 347


 

(557


)


 

1 213


 


 

144 003


 

0.9


%


 

1.1


%


 

HY25


 

Scope


 

Organic


 

HY26


 

Organic growth


 

growth


 

Total


 

Beer


North America


 

42 218


 

121


 


 

(779


)


 

41 561


 

(1.8


)%


 

(1.9


)%


Middle Americas


 

73 903


 

(1 362


)


 

3 439


 


 

75 979


 

4.7


%


 

5.2


%


South America


 

75 089


 

-


 


 

341


 


 

75 430


 

0.5


%


 

2.2


%


EMEA


 

44 924


 

(230


)


 

476


 


 

45 169


 

1.1


%


 

1.2


%


Asia Pacific


 

43 365


 

(39


)


 

(1 192


)


 

42 134


 

(2.8


)%


 

(2.7


)%


Global Export and Holding Companies


 

116


 

22


 


 

1


 


 

139


 

0.8


%


 

0.8


%


AB InBev Worldwide


 

279 615


 

(1 489


)


 

2 286


 


 

280 412


 

0.8


%


 

1.2


%


Key Markets Performance


United States: Portfolio momentum drove beer and Beyond Beer share gains and continued top-line growth


Operating performance:


2Q26: Revenue increased by 2.7%, with revenue per hl increasing by 3.3% driven by revenue management and positive brand mix. Sales-to-retailers (STRs) declined by 1.9%, estimated to have outperformed a soft industry. Sales-to-wholesalers (STWs) declined by 0.6%. EBITDA increased by 0.1%, as top-line growth and productivity initiatives were reinvested in increased marketing to fuel momentum.


HY26: Revenue increased by 1.9%, with revenue per hl increasing by 3.8%. STRs declined by 0.9% and STWs were down by 1.8%. Our STRs and STWs tend to converge on a full year basis. EBITDA increased by 0.2%.


Commercial highlights: We were the #1 share gainer in total alcohol in both 2Q26 and HY26 driven by share gains in both beer and spirits, according to Circana. Our beer performance in 2Q26 was led by Michelob Ultra, Busch Light and Busch Light Apple, which were the top 3 volume share gainers in the industry. Our Beyond Beer portfolio continued to expand our total addressable market and delivered revenue growth in the mid-seventies. Cutwater grew revenue in the triple-digits and was the #1 share gaining brand in the total spirits industry. We are the leader in no-alcohol beer, with our portfolio gaining share and growing revenue in the mid-thirties led by Michelob Ultra Zero which was the #1 share gainer in no-alcohol beer.


Mexico: Market share gain and margin expansion drove mid-single digit top- and high-single digit bottom-line growth


Operating performance:


2Q26: Revenue and revenue per hl increased by mid-single digits, driven by revenue management and positive mix. Volumes grew slightly and outperformed the industry. EBITDA grew by high-single digits with margin expansion.


HY26: Revenue grew by mid-single digits, with revenue per hl growth of mid-single digits and volume increasing by low-single digits, outperforming the industry. EBITDA grew by mid-single digits with flattish margins as top-line growth and productivity initiatives offset transactional FX headwinds and enabled increased marketing investment.


Commercial highlights: We are strengthening our portfolio architecture and expanding our total addressable market by offering consumers more choices across more occasions. Performance in 2Q26 was led by our above core beer portfolio, which grew revenue by high-single digits driven by Modelo and Pacifico, while our mainstream beer portfolio grew by mid-single digits. We strengthened our position as the industry leader in no-alcohol beer, with our portfolio growing volume by high-thirties led by Modelo Cero and the launch of Michelob Ultra Zero. In Beyond Beer, our portfolio grew volume by high-teens, led by the Vicky’s brand family and Flying Fish.


Colombia: Record high volumes drove double-digit top- and bottom-line growth


Operating performance:


2Q26: Revenue increased by high-teens, with high-single digit revenue per hl growth driven by revenue management and premiumization. Volumes grew by low-teens, with our portfolio estimated to have gained share of total alcohol. EBITDA grew by high-teens as top-line growth and productivity initiatives offset transactional FX headwinds and enabled increased marketing investment.


HY26: Revenue grew by mid-teens with mid-single digit revenue per hl growth. Volumes increased by high-single digits. EBITDA grew by mid-teens.


Commercial highlights: Increased brand power drove momentum across our portfolio, with volume and revenue growth across all price segments in 2Q26 and record high second quarter volumes. Above core beer led our performance, with mid-teens volume growth driven by Corona. Our mainstream beer portfolio continued to grow, delivering a high-single digit volume increase.


Brazil: Market share gain and an improved industry drove beer volume growth and a double-digit bottom-line increase


Operating performance:


2Q26: Revenue increased by 7.8%, with revenue per hl growth of 5.3% driven by revenue management and premiumization. Beer volumes increased by 5.0%, estimated to have outperformed an improved industry. Non-beer volumes decreased by 4.4%, resulting in total volume growth of 2.3%. EBITDA increased by 16.1% with 230bps of margin expansion as disciplined revenue and cost management more than offset increased sales and marketing investment.


HY26: Revenue grew by 8.1% with revenue per hl growth of 7.1%. Beer volumes grew by 2.9% and non-beer volumes declined by 4.1%, resulting in total volume growth of 0.9%. EBITDA increased by 13.1% with 149bps of margin expansion.


Commercial highlights: Innovation and investment behind our megabrands and mega platforms strengthened our portfolio brand power and drove continued market share gains. Premium and super premium beer led our performance in 2Q26, delivering mid-twenties volume growth and strengthening our leadership position of the premium segment. Mainstream beer improved sequentially, delivering flattish volumes and estimated to have gained share of the segment. We are leading the industry in Balanced Choices, with volumes of our no-alcohol beer portfolio growing in the low-thirties and Stella Artois Pure Gold and Michelob Ultra growing by triple digits. In Beyond Beer, our portfolio grew volumes by strong double digits, led by Beats and Flying Fish.


Europe: Volume growth and premiumization drove a low-single digit top-line increase


Operating performance:


2Q26: Volumes grew by low-single digits, estimated to have gained or maintained share in the majority of our key markets. Revenue and revenue per hl increased by low-single digits driven by premiumization. EBITDA declined by low-single digits, with top-line growth primarily offset by increased sales and marketing investment.


HY26: Volumes grew by low-single digits, estimated to have gained share in 5 of our 6 key markets. Revenue and revenue per hl increased by low-single digits driven by premiumization. EBITDA declined by low-single digits.


Commercial highlights: Market share gains, innovation and premiumization drove low-single digit volume growth in both 2Q26 and HY26. Our performance in 2Q26 was driven by our megabrands, led by Corona which delivered mid-teens volume growth. We are building strong consumer connection with our brands through our mega platforms and innovations. We successfully activated Roland Garros with Stella Artois, launched Stella Artois Strawberries & Cream ahead of Wimbledon and expanded the availability of Modelo Especial in the UK. Our no-alcohol beer portfolio grew volumes by low-teens, led by Corona Cero.


South Africa: Disciplined revenue management and margin expansion drove mid-single digit top- and bottom-line growth


Operating performance:


2Q26: Revenue and revenue per hl increased by mid-single digits, driven by revenue management and premiumization. Volumes declined by low-single digits, underperforming the industry. Beyond Beer volumes grew and are estimated to have outperformed. EBITDA grew by mid-single digits with margin expansion.


HY26: Revenue and revenue per hl increased by mid-single digits. Volumes grew by low-single digits. EBITDA grew by low-single digits, with top-line growth partially offset by increased marketing investment.


Commercial highlights: Investment in our megabrands and innovations drove increased portfolio brand power in 2Q26. Premium and super premium beer led our performance, delivering high-twenties volume growth and estimated to have gained share of the segment. In Beyond Beer, our portfolio gained share and grew volumes by low-twenties.


China: Top- and bottom-line declined, impacted by volume performance in a soft industry


Operating performance:


2Q26: Volumes declined by 9.7%, estimated to have underperformed a soft industry, which was impacted by adverse weather and continued weakness in the on-premise channel. Revenue per hl increased by 1.0% driven by positive brand mix, resulting in a revenue decline of 8.8%. EBITDA declined by 16.1%, impacted by top-line performance.


HY26: Volumes declined by 6.0%. Revenue per hl decreased by 0.5% resulting in a revenue decline of 6.5%. EBITDA declined by 13.9%.


Commercial highlights: Beer industry volumes are estimated to have declined by mid-single digits in 2Q26, reflecting adverse weather and softness in the on-premise channel. Our market share trend is estimated to have improved sequentially, supported by a return to growth in our super premium and core plus brands in the second quarter. Investment in our megabrands and innovations strengthened our portfolio brand power in the quarter. We remain focused on improving execution and expanding our in‑home channel presence to rebuild momentum and better position our business for ongoing channel shifts in the industry.


Highlights from our other markets


Canada: Revenue grew by low-single digits in 2Q26 with mid-single digit revenue per hl growth driven by revenue management and positive brand mix. Our portfolio was estimated to be the #1 share gainer in both beer and Beyond Beer, while volumes declined by low-single digits amid a soft industry. Our beer performance was led by Michelob Ultra and Busch, which were the top two volume share gainers in the industry. Beyond Beer growth was led by Cutwater and Mike’s Hard Lemonade, two of the top four share gainers in the category.


Peru: Volumes grew by high-single digits in 2Q26 with our portfolio estimated to have gained share of total alcohol. Performance was led by our mainstream beer brands which grew volumes by mid-single digits, and our Beyond Beer portfolio, which grew volumes in the triple-digits. Revenue grew by high-single digits with low-single digit revenue per hl growth.


Ecuador: Volumes grew by mid-twenties in 2Q26 to reach a record high for the second quarter, driven by estimated market share gains and a strong industry in an improved consumer environment. Performance was led by our above core beer portfolio, which grew volumes by strong double digits. Revenue grew by high-twenties with low-single digit revenue per hl growth.


Argentina: Beer volumes grew by low-single digits in 2Q26, estimated to have outperformed an improved industry. Total volumes declined by low-single digits, impacted by a soft non-beer industry. Revenue grew by mid-teens, driven by revenue management.


Africa excluding South Africa: In 2Q26, Nigeria total volumes and revenue declined by low-single digits, impacted by a soft consumer environment.

In our other markets in Africa, revenue grew in aggregate by high-single digits and volumes by mid-single digits.


South Korea: Volume increased by low-teens in 2Q26 cycling an easier comparable due to shipment phasing ahead of our April 2025 price increase. Revenue grew by high-single digits, with a low-single digit revenue per hl decline driven by negative packaging mix. We estimate that we continued to gain market share in both the on-premise and in-home channels.


Consolidated Income Statement


Figure 3. Consolidated income statement


in USD Mio


 

2Q25


 

2Q26


 

Organic


 

growth


Revenue


 

15 004


 


 

16 660


 


 

5.6


%


Cost of sales


 

(6 558


)


 

(7 082


)


 

(3.2


)%


Gross profit


 

8 446


 


 

9 579


 


 

7.5


%


SG&A


 

(4 624


)


 

(5 175


)


 

(6.5


)%


Other operating income/(expenses)


 

191


 


 

200


 


 

(7.9


)%


Normalized EBIT


 

4 013


 


 

4 604


 


 

8.0


%


Non-underlying items above EBIT


 

(45


)


 

(42


)


   

Net finance income/(expense)


 

(1 062


)


 

(1 057


)


   

Non-underlying net finance income/(expense)


 

(234


)


 

1 402


 


   

Share of results of associates


 

84


 


 

96


 


   

Non-underlying share of results of associates


 

9


 


 

-


 


   

Income tax expense


 

(741


)


 

(918


)


   

Profit


 

2 024


 


 

4 084


 


   

Profit attributable to non-controlling interest


 

347


 


 

333


 


   

Profit attributable to equity holders of AB InBev


 

1 676


 


 

3 751


 


   

   

Normalized EBITDA


 

5 301


 


 

5 938


 


 

5.8


%


Underlying Profit


 

1 950


 


 

2 390


 


 

 


 

HY25


 

HY26


 

Organic


 

growth


Revenue


 

28 632


 


 

31 927


 


 

5.7


%


Cost of sales


 

(12 602


)


 

(13 702


)


 

(3.6


)%


Gross profit


 

16 029


 


 

18 225


 


 

7.4


%


SG&A


 

(8 812


)


 

(9 917


)


 

(6.5


)%


Other operating income/(expenses)


 

383


 


 

369


 


 

(9.7


)%


Normalized EBIT


 

7 601


 


 

8 677


 


 

7.6


%


Non-underlying items above EBIT


 

(94


)


 

14


 


   

Net finance income/(expense)


 

(2 046


)


 

(2 107


)


   

Non-underlying net finance income/(expense)


 

368


 


 

2 033


 


   

Share of results of associates


 

135


 


 

148


 


   

Non-underlying share of results of associates


 

9


 


 

-


 


   

Income tax expense


 

(1 404


)


 

(1 704


)


   

Profit


 

4 568


 


 

7 061


 


   

Profit attributable to non-controlling interest


 

744


 


 

747


 


   

Profit attributable to equity holders of AB InBev


 

3 824


 


 

6 314


 


   

   

Normalized EBITDA


 

10 156


 


 

11 375


 


 

5.6


%


Underlying Profit


 

3 556


 


 

4 314


 


 

 


Non-underlying items above EBIT & Non-underlying share of results of associates


Figure 4. Non-underlying items above EBIT & Non-underlying share of results of associates


in USD Mio


 

2Q25


 

2Q26


 

HY25


 

HY26


Restructuring


 

(35


)


 

(11


)


 

(47


)


 

(33


)


Business and asset disposals (including impairment losses)


 

(10


)


 

(17


)


 

(47


)


 

61


 


Acquisition-related costs (business combinations)


 

-


 


 

(14


)


 

-


 


 

(14


)


Non-underlying items in EBIT


 

(45


)


 

(42


)


 

(94


)


 

14


 


Non-underlying share of results of associates


 

9


 


 

-


 


 

9


 


 

-


 


Normalized EBIT excludes negative non-underlying items of 42 million USD in 2Q26 and positive non-underlying items of 14 million USD in HY26.


Net finance income/(expense)


Figure 5. Net finance income/(expense)


in USD Mio


 

2Q25


 

2Q26


 

HY25


 

HY26


Net interest expense


 

(663


)


 

(583


)


 

(1 284


)


 

(1 196


)


Accretion expense and interest on pensions


 

(184


)


 

(196


)


 

(351


)


 

(413


)


Other financial results


 

(214


)


 

(278


)


 

(410


)


 

(498


)


Net finance income/(expense)


 

(1 062


)


 

(1 057


)


 

(2 046


)


 

(2 107


)


Non-underlying net finance income/(expense)


Figure 6. Non-underlying net finance income/(expense)


in USD Mio


 

2Q25


 

2Q26


 

HY25


 

HY26


Mark-to-market


 

(263


)


 

1 402


 

339


 

2 033


Gain/(loss) on bond redemption and other


 

29


 


 

-


 

29


 

-


Non-underlying net finance income/(expense)


 

(234


)


 

1 402


 

368


 

2 033


Non-underlying net finance income includes mark-to-market gains on derivative instruments entered into in order to hedge our share-based payment programs and shares issued in relation to the combinations with Grupo Modelo and SAB.


The number of shares covered by the hedging of our share-based payment program, the deferred share instrument and the restricted shares are shown below, together with the opening and closing share prices.


Figure 7. Non-underlying equity derivative instruments


 

2Q25


 

2Q26


 

HY25


 

HY26


Share price at the start of the period (Euro)


 

56.92


 

59.72


 

48.25


 

54.90


Share price at the end of the period (Euro)


 

58.24


 

72.66


 

58.24


 

72.66


Number of equity derivative instruments at the end of the period (in million)


 

100.5


 

90.5


 

100.5


 

90.5


Income tax expense


Figure 8. Income tax expense


in USD Mio


 

2Q25


 

2Q26


 

HY25


 

HY26


Income tax expense


 

741


 

918


 

1 404


 

1 704


Effective tax rate


 

27.7%


 

18.7%


 

24.1%


 

19.8%


Normalized effective tax rate


 

25.3%


 

26.1%


 

25.6%


 

25.7%


The HY26 and HY25 effective tax rates were positively impacted by non-taxable gains from derivatives related to the hedging of share-based payment programs and the hedging of the shares issued in a transaction related to the combinations with Grupo Modelo and SAB. The increase in Normalized ETR in HY26 compared to HY25 was primarily due to negative country mix.


Underlying EPS


Figure 9. Underlying EPS


in USD per share, except number of shares in million


 

2Q25


 

2Q26


 

HY25


 

HY26


Normalized EBITDA


 

2.67


 


 

3.01


 


 

5.11


 


 

5.76


 


Depreciation, amortization and impairment


 

(0.65


)


 

(0.68


)


 

(1.28


)


 

(1.37


)


Normalized EBIT


 

2.02


 


 

2.33


 


 

3.82


 


 

4.39


 


Net finance income/(expense)


 

(0.53


)


 

(0.54


)


 

(1.03


)


 

(1.07


)


Income tax expense


 

(0.38


)


 

(0.47


)


 

(0.71


)


 

(0.85


)


Associates & non-controlling interests


 

(0.13


)


 

(0.12


)


 

(0.31


)


 

(0.31


)


Hyperinflation impacts


 

0.01


 


 

0.00


 


 

0.02


 


 

0.02


 


Underlying EPS


 

0.98


 


 

1.21


 


 

1.79


 


 

2.18


 


Weighted average number of ordinary and restricted shares


 

1 989


 


 

1 976


 


 

1 989


 


 

1 976


 


Reconciliation of IFRS and Non-IFRS Financial Measures


Profit attributable to equity holders and Underlying Profit


Figure 10. Underlying Profit


in USD Mio


 

2Q25


 

2Q26


 

HY25


 

HY26


Profit attributable to equity holders of AB InBev


 

1 676


 

3 751


 


 

3 824


 


 

6 314


 


Net impact of non-underlying items on profit


 

261


 

(1 367


)


 

(305


)


 

(2 034


)


Hyperinflation impacts


 

14


 

7


 


 

37


 


 

35


 


Underlying Profit


 

1 950


 

2 390


 


 

3 556


 


 

4 314


 


Basic and Underlying EPS


Figure 11. Basic and Underlying EPS


in USD per share, except number of shares in million


 

2Q25


 

2Q26


 

HY25


 

HY26


Basic EPS


 

0.84


 

1.90


 


 

1.92


 


 

3.20


 


Net impact of non-underlying items


 

0.13


 

(0.69


)


 

(0.15


)


 

(1.03


)


Hyperinflation impacts


 

0.01


 

0.00


 


 

0.02


 


 

0.02


 


Underlying EPS


 

0.98


 

1.21


 


 

1.79


 


 

2.18


 


FX translation impact


 

-


 

(0.10


)


 

-


 


 

(0.20


)


Underlying EPS in constant currency


 

0.98


 

1.11


 


 

1.79


 


 

1.98


 


Weighted average number of ordinary and restricted shares


 

1 989


 

1 976


 


 

1 989


 


 

1 976


 


Profit attributable to equity holders and Normalized EBITDA


Figure 12. Reconciliation of Normalized EBITDA to Profit attributable to equity holders of AB InBev


in USD Mio


 

2Q25


 

2Q26


 

HY25


 

HY26


Profit attributable to equity holders of AB InBev


 

1 676


 


 

3 751


 


 

3 824


 


 

6 314


 


Non-controlling interests


 

347


 


 

333


 


 

744


 


 

747


 


Profit


 

2 024


 


 

4 084


 


 

4 568


 


 

7 061


 


Income tax expense


 

741


 


 

918


 


 

1 404


 


 

1 704


 


Share of results of associates


 

(84


)


 

(96


)


 

(135


)


 

(148


)


Non-underlying share of results of associates


 

(9


)


 

-


 


 

(9


)


 

-


 


Net finance (income)/expense


 

1 062


 


 

1 057


 


 

2 046


 


 

2 107


 


Non-underlying net finance (income)/expense


 

234


 


 

(1 402


)


 

(368


)


 

(2 033


)


Non-underlying items above EBIT (incl. impairment losses)


 

45


 


 

42


 


 

94


 


 

(14


)


Normalized EBIT


 

4 013


 


 

4 604


 


 

7 601


 


 

8 677


 


Depreciation, amortization and impairment


 

1 288


 


 

1 335


 


 

2 555


 


 

2 698


 


Normalized EBITDA


 

5 301


 


 

5 938


 


 

10 156


 


 

11 375


 


Normalized EBITDA, Normalized EBIT and Underlying Profit are non-IFRS financial measures used by AB InBev to reflect the company’s underlying performance. Underlying EPS and constant currency Underlying EPS are non-IFRS financial measures that AB InBev believes are useful to investors because they facilitate comparisons of EPS from period to period.


Normalized EBITDA is calculated by adjusting profit attributable to equity holders of AB InBev to exclude: (i) non-controlling interest; (ii) income tax expense; (iii) share of results of associates; (iv) non-underlying share of results of associates; (v) net finance income or cost; (vi) non-underlying net finance income or cost; (vii) non-underlying items above EBIT; and (viii) depreciation, amortization and impairment.


Underlying Profit is calculated by adjusting profit attributable to equity holders of AB InBev to exclude: (i) non-underlying items and (ii) hyperinflation impacts. Underlying EPS is calculated as Underlying Profit divided by the weighted average number of ordinary and restricted shares. Constant currency Underlying EPS is calculated as Underlying EPS excluding the effects of foreign currency translation by translating current period figures using the exchange rates from the same period in the prior year.


Normalized EBITDA, Normalized EBIT and Underlying Profit are not accounting measures under IFRS and should not be considered as an alternative to profit attributable to equity holders as a measure of operational performance, or an alternative to cash flow as a measure of liquidity. Underlying EPS and constant currency Underlying EPS are not accounting measures under IFRS and should not be considered as alternatives to earnings per share as a measure of operating performance on a per share basis. These non-IFRS financial measures do not have a standard calculation method and AB InBev’s definition of Normalized EBITDA, Normalized EBIT, Underlying Profit, Underlying EPS and constant currency Underlying EPS may not be comparable to that of other companies.


Cash Flows and Financial position


Figure 13. Cash Flow Statement (million USD)


 

HY25


 

HY26


Operating activities


   

Profit of the period


 

4 568


 


 

7 061


 


Interest, taxes and non-cash items included in profit


 

5 736


 


 

4 459


 


Cash flow from operating activities before changes in working capital and use of provisions


 

10 304


 


 

11 520


 


 


   

Change in working capital


 

(3 655


)


 

(2 355


)


Pension contributions and use of provisions


 

(278


)


 

(158


)


Interest and taxes (paid)/received


 

(3 801


)


 

(3 866


)


Dividends received


 

135


 


 

101


 


Cash flow from/(used in) operating activities


 

2 704


 


 

5 241


 


 


   

Investing activities


   

Net capex


 

(1 350


)


 

(1 360


)


Sale/(acquisition) and others related to subsidiaries, net of cash


 

(4


)


 

(757


)


Net proceeds from sale/(acquisition) of other assets


 

47


 


 

310


 


Cash flow from/(used in) investing activities


 

(1 306


)


 

(1 807


)


 


   

Financing activities


   

Net (repayments of) / proceeds from borrowings


 

68


 


 

246


 


Dividends paid


 

(3 147


)


 

(2 596


)


Share buyback


 

(1 901


)


 

(1 301


)


Payment of lease liabilities


 

(354


)


 

(364


)


Derivative financial instruments


 

114


 


 

(319


)


Sale/(acquisition) of non-controlling interests


 

(314


)


 

(3 389


)


Other financing cash flows


 

(303


)


 

219


 


Cash flow from/(used in) financing activities


 

(5 837


)


 

(7 505


)


 


   

Net increase/(decrease) in cash and cash equivalents


 

(4 438


)


 

(4 071


)


Our free cash flow (defined as cash flow from operating activities less net capex) increased by 2 526 million USD to reach 3 881 million USD in HY26. Our cash and cash equivalents decreased by (4 071) million USD in HY26, compared to a decrease of (4 438) million USD in HY25, with the following movements:


Our cash flow from operating activities reached 5 241 million USD in HY26 compared to 2 704 million USD in HY25. The increase was driven by increased profit of the period and changes in working capital for HY26 compared to HY25. Changes in working capital in the first half of 2026 and 2025 reflect higher working capital levels at the end of June than at year-end as a result of seasonality.


Our cash outflow from investing activities was 1 807 million USD in HY26 compared to a cash outflow of 1 306 million USD in HY25. The increase in the cash outflow was mainly due to the acquisition of an 85% controlling stake in BeatBox, a ready-to-drink alcohol beverage business in the United States. Out of the total HY26 capital expenditures, approximately 25% was used to improve the company’s production facilities while 60% was used for logistics and commercial investments and 15% was used for the purchase of hardware and software and improving administrative capabilities.


Our cash outflow from financing activities amounted to 7 505 million USD in HY26, as compared to a cash outflow of 5 837 million USD in HY25. The increase in the cash outflow versus HY25 was primarily driven by the completion of the reacquisition of the 49.9% minority stake in our US-based metal container plants for 2.9 billion USD.


Our net debt increased to 64.2 billion USD as of 30 June 2026 from 60.9 billion USD as of 31 December 2025. Our net debt to normalized EBITDA ratio was 2.86x as of 30 June 2026. Our optimal capital structure is a net debt to normalized EBITDA ratio of around 2x.


We continue to proactively manage our debt portfolio. 98% of our bond portfolio holds a fixed-interest rate, 52% is denominated in currencies other than USD and maturities are well-distributed across the next several years.


As of 30 June 2026, we had total liquidity of 18.1 billion USD, which consisted of 10.1 billion USD available under committed long-term credit facilities and 8.0 billion USD of cash, cash equivalents and short-term investments in debt securities less bank overdrafts.


Notes


To facilitate the understanding of AB InBev’s underlying performance, the analyses of growth, including all comments in this press release, unless otherwise indicated, are based on organic growth and normalized numbers. In other words, financials are analyzed eliminating the impact of changes in currencies on translation of foreign operations, and scope changes. Since 1Q24, the definition of organic revenue growth has been amended to cap the price growth in Argentina to a maximum of 2% per month (26.8% year-over-year). Corresponding adjustments are made to all income statement related items in the organic growth calculations through scope changes. Scope changes also represent the impact of acquisitions and divestitures, the start or termination of activities or the transfer of activities between segments, curtailment gains and losses and year over year changes in accounting estimates and other assumptions that management does not consider as part of the underlying performance of the business. Beer volumes and revenue include primarily beer, no-alcohol beer, other malt-based alcohol beverages and spirits-based beverages. Non-beer volumes and revenue include primarily carbonated soft drinks and energy drinks. In addition, beer and non-beer categories include not only brands that we own or license, but also third-party brands that we brew and sell, and third-party products that we sell through our distribution network. The organic growth of our global brands, Budweiser, Stella Artois, and Corona excludes exports to Australia for which a perpetual license was granted to a third party upon disposal of the Australia operations in 2020. All references per hectoliter (per hl) exclude US non-beverage activities. Whenever presented in this document, all performance measures (EBITDA, EBIT, profit, tax rate, EPS) are presented on a “normalized” basis, which means they are presented before non-underlying items. Non-underlying items are either income or expenses which do not occur regularly as part of the normal activities of the Company. They are presented separately because they are important for the understanding of the underlying sustainable performance of the Company due to their size or nature. Normalized measures are additional measures used by management and should not replace the measures determined in accordance with IFRS as an indicator of the Company’s performance. Effective 1 January 2026, Cervecería Bucanero S.A., a Cuban company in which we indirectly hold a 50% equity interest through our subsidiary Ambev, is accounted for as an associate using the equity method of accounting. The impact of this change in presentation is reflected as a scope change. We are reporting the results from Argentina applying hyperinflation accounting since 3Q18. The IFRS rules (IAS 29) require us to restate the year-to-date results for the change in the general purchasing power of the local currency, using official indices before converting the local amounts at the closing rate of the period. In 2Q26, we reported a negative impact from hyperinflation accounting on the profit attributable to equity holders of AB InBev of 7 million USD. The impact in 2Q26 Basic EPS was less than 0.01 USD. Values in the figures and annexes may not add up, due to rounding. 2Q26 and HY26 EPS is based upon a weighted average of 1 976 million shares compared to a weighted average of 1 989 million shares for 2Q25 and HY25.


Legal disclaimer


This release contains “forward-looking statements”. These statements are based on the current expectations and views of future events and developments of the management of AB InBev and are naturally subject to uncertainty and changes in circumstances. The forward-looking statements contained in this release include statements other than historical facts and include statements typically containing words such as “will”, “may”, “should”, “believe”, “intends”, “expects”, “anticipates”, “targets”, “ambition”, “estimates”, “likely”, “foresees” and words of similar import. All statements other than statements of historical facts are forward-looking statements. You should not place undue reliance on these forward-looking statements, which reflect the current views of the management of AB InBev, are subject to numerous risks and uncertainties about AB InBev and are dependent on many factors, some of which are outside of AB InBev’s control. There are important factors, risks and uncertainties that could cause actual outcomes and results to be materially different, including, but not limited to the risks and uncertainties relating to AB InBev that are described under Item 3.D of AB InBev’s Annual Report on Form 20-F filed with the SEC on 3 March 2026. Many of these risks and uncertainties are, and will be, exacerbated by any further worsening of the global business and economic environment, including as a result of foreign currency exchange rate fluctuations and ongoing geopolitical instability. Other unknown or unpredictable factors could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements should be read in conjunction with the other cautionary statements that are included elsewhere, including AB InBev’s most recent Form 20-F and other reports furnished on Form 6-K, and any other documents that AB InBev has made public. Any forward-looking statements made in this communication are qualified in their entirety by these cautionary statements and there can be no assurance that the actual results or developments anticipated by AB InBev will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, AB InBev or its business or operations. Except as required by law, AB InBev undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The half year 2026 (HY26) financial data set out in Figure 1 (except for the volume information), Figures 3 to 6, 8, 10, 12 and 13 of this press release have been extracted from the group’s unaudited condensed consolidated interim financial statements as of and for the six-month period ended 30 June 2026, which have been reviewed by our statutory auditors PwC Bedrijfsrevisoren BV/Reviseurs d’Entreprises SRL in accordance with the standards of the Public Company Accounting Oversight Board (United States). The second quarter 2026 (2Q26) financial data set out in Figure 1 (except for the volume information), Figures 3 to 6, 8, 10, 12 and 13, and the financial data included in Figures 7, 9, 11 and 14 of this press release have been extracted from the underlying accounting records as of and for the six-month period ended 30 June 2026. The interim sustainability data set out on page 3 are from unaudited internal databases. These have been calculated on a consistent basis with the group’s consolidated sustainability statements as of and for the twelve months ended 31 December 2025, for which limited assurance was provided by our statutory auditors PwC Bedrijfsrevisoren BV/Reviseurs d’Entreprises SRL in accordance with CSRD. References in this document to materials on our websites, such as www.ab-inbev.com, are included as an aid to their location and are not incorporated by reference into this document.


Conference call and webcast


Investor Conference call and webcast on Thursday, 30 July 2026:

3.00pm Brussels / 2.00pm London / 9.00am New York


Registration details:

Webcast (listen-only mode):

AB InBev 2Q26 Results Webcast


To join by phone, please use one of the following two phone numbers:

Toll-Free: +1-877-407-8029

Toll: +1-201-689-8029


About AB InBev


Anheuser-Busch InBev (AB InBev) is a publicly traded company (Euronext: ABI) based in Leuven, Belgium, with secondary listings on the Mexico (MEXBOL: ANB) and South Africa (JSE: ANH) stock exchanges and with American Depositary Receipts on the New York Stock Exchange (NYSE: BUD). As a company, we dream big to create a future with more cheers. We are always looking to serve up new ways to meet life’s moments, move our industry forward and make a meaningful impact in the world. We are committed to building great brands that stand the test of time and to brewing the best beers using the finest ingredients. Beer is the drink for moderation, and for over a century, AB InBev has championed responsible drinking. We are committed to providing our consumers with Balanced Choices to enjoy on any occasion. We also invest in marketing that aims to reinforce positive behaviors, and we work with communities, customers, and partners to promote responsible consumption through evidence-based initiatives.


Our diverse portfolio of well over 400 beer brands includes global brands Budweiser®, Corona®, Stella Artois® and Michelob Ultra®; multi-country brands Beck’s®, Hoegaarden® and Leffe®; and local champions such as Aguila®, Antarctica®, Bud Light®, Brahma®, Cass®, Castle®, Castle Lite®, Cristal®, Harbin®, Jupiler®, Modelo Especial®, Quilmes®, Victoria®, Sedrin®, and Skol®. Our brewing heritage dates back more than 600 years, spanning continents and generations. From our European roots at the Den Hoorn brewery in Leuven, Belgium. To the pioneering spirit of the Anheuser & Co brewery in St. Louis, US. To the creation of the Castle Brewery in South Africa during the Johannesburg gold rush. To Bohemia, the first brewery in Brazil. Geographically diversified with a balanced exposure to developed and developing markets, we leverage the collective strengths of approximately 137 000 colleagues based in more than 40 countries worldwide. For 2025, AB InBev’s reported revenue was 59.3 billion USD (excluding JVs and associates).


Annex 1: Segment reporting (2Q)


AB InBev Worldwide


 

2Q25


 

Scope


 

Currency

Translation


 

Organic

Growth


 

2Q26


 

Organic

Growth


Volumes


 

143 347


 


 

(557


)


 

-


 


 

1 213


 


 

144 003


 


 

0.9


%


Revenue


 

15 004


 


 

(6


)


 

822


 


 

840


 


 

16 660


 


 

5.6


%


Cost of sales


 

(6 558


)


 

13


 


 

(326


)


 

(211


)


 

(7 082


)


 

(3.2


)%


Gross profit


 

8 446


 


 

6


 


 

496


 


 

630


 


 

9 579


 


 

7.5


%


SG&A


 

(4 624


)


 

(41


)


 

(209


)


 

(300


)


 

(5 175


)


 

(6.5


)%


Other operating income/(expenses)


 

191


 


 

7


 


 

17


 


 

(15


)


 

200


 


 

(7.9


)%


Normalized EBIT


 

4 013


 


 

(28


)


 

304


 


 

315


 


 

4 604


 


 

8.0


%


Normalized EBITDA


 

5 301


 


 

(34


)


 

370


 


 

301


 


 

5 938


 


 

5.8


%


Normalized EBITDA margin


 

35.3


%


 

35.6


%


 

4bps


   

North America


 

2Q25


 

Scope


 

Currency

Translation


 

Organic

Growth


 

2Q26


 

 


Organic

Growth


Volumes


 

22 376


 


 

218


 


 

-


 


 

(164


)


 

22 430


 


 

(0.7


)%


Revenue


 

3 844


 


 

90


 


 

7


 


 

99


 


 

4 039


 


 

2.6


%


Cost of sales


 

(1 537


)


 

(36


)


 

(2


)


 

(2


)


 

(1 577


)


 

(0.1


)%


Gross profit


 

2 307


 


 

53


 


 

5


 


 

97


 


 

2 463


 


 

4.2


%


SG&A


 

(1 122


)


 

(30


)


 

(2


)


 

(77


)


 

(1 232


)


 

(6.9


)%


Other operating income/(expenses)


 

10


 


 

0


 


 

(0


)


 

6


 


 

16


 


 

61.7


%


Normalized EBIT


 

1 195


 


 

23


 


 

3


 


 

26


 


 

1 247


 


 

2.2


%


Normalized EBITDA


 

1 372


 


 

27


 


 

3


 


 

6


 


 

1 408


 


 

0.5


%


Normalized EBITDA margin


 

35.7


%


 

34.9


%


 

(74)bps


 


   

Middle Americas


 

2Q25


 

Scope


 

Currency

Translation


 

Organic

Growth


 

2Q26


 

Organic

Growth


Volumes


 

38 822


 


 

(634


)


 

-


 


 

1 806


 


 

39 994


 


 

4.7


%


Revenue


 

4 340


 


 

(77


)


 

408


 


 

419


 


 

5 091


 


 

9.8


%


Cost of sales


 

(1 516


)


 

42


 


 

(132


)


 

(91


)


 

(1 697


)


 

(6.2


)%


Gross profit


 

2 824


 


 

(35


)


 

276


 


 

328


 


 

3 394


 


 

11.8


%


SG&A


 

(987


)


 

13


 


 

(91


)


 

(95


)


 

(1 160


)


 

(9.8


)%


Other operating income/(expenses)


 

3


 


 

1


 


 

(1


)


 

(16


)


 

(14


)


 

-


 


Normalized EBIT


 

1 839


 


 

(21


)


 

185


 


 

217


 


 

2 220


 


 

11.9


%


Normalized EBITDA


 

2 149


 


 

(20


)


 

211


 


 

220


 


 

2 560


 


 

10.3


%


Normalized EBITDA margin


 

49.5


%


 

50.3


%


 

23bps


   

South America


 

2Q25


 

Scope


 

Currency

Translation


 

Organic

Growth


 

2Q26


 

 


Organic

Growth


Volumes


 

34 199


 


 

-


 


 

-


 


 

466


 


 

34 665


 


 

1.4


%


Revenue


 

2 529


 


 

6


 


 

236


 


 

191


 


 

2 961


 


 

7.6


%


Cost of sales


 

(1 314


)


 

(14


)


 

(106


)


 

(29


)


 

(1 463


)


 

(2.2


)%


Gross profit


 

1 215


 


 

(8


)


 

130


 


 

162


 


 

1 499


 


 

13.4


%


SG&A


 

(863


)


 

(4


)


 

(67


)


 

(78


)


 

(1 012


)


 

(9.0


)%


Other operating income/(expenses)


 

104


 


 

9


 


 

15


 


 

19


 


 

146


 


 

18.7


%


Normalized EBIT


 

456


 


 

(4


)


 

77


 


 

103


 


 

633


 


 

23.0


%


Normalized EBITDA


 

692


 


 

1


 


 

94


 


 

99


 


 

886


 


 

14.3


%


Normalized EBITDA margin


 

27.4


%


 

29.9


%


 

171bps


EMEA


 

2Q25


 

Scope


 

Currency

Translation


 

Organic

Growth


 

2Q26


 

Organic

Growth


Volumes


 

24 172


 


 

(135


)


 

-


 


 

201


 


 

24 239


 


 

0.8


%


Revenue


 

2 489


 


 

(37


)


 

145


 


 

81


 


 

2 677


 


 

3.3


%


Cost of sales


 

(1 252


)


 

21


 


 

(73


)


 

(17


)


 

(1 321


)


 

(1.3


)%


Gross profit


 

1 237


 


 

(17


)


 

72


 


 

65


 


 

1 357


 


 

5.3


%


SG&A


 

(764


)


 

(6


)


 

(37


)


 

(35


)


 

(841


)


 

(4.5


)%


Other operating income/(expenses)


 

56


 


 

(3


)


 

1


 


 

(15


)


 

39


 


 

(28.9


)%


Normalized EBIT


 

529


 


 

(25


)


 

35


 


 

14


 


 

554


 


 

2.9


%


Normalized EBITDA


 

800


 


 

(21


)


 

51


 


 

13


 


 

843


 


 

1.7


%


Normalized EBITDA margin


 

32.1


%


 

31.5


%


 

(49)bps


 


   

Asia Pacific


 

2Q25


 

Scope


 

Currency

Translation


 

Organic

Growth


 

2Q26


 

Organic

Growth


Volumes


 

23 716


 


 

(21


)


 

-


 


 

(1 109


)


 

22 586


 


 

(4.7


)%


Revenue


 

1 658


 


 

11


 


 

26


 


 

(47


)


 

1 648


 


 

(2.8


)%


Cost of sales


 

(771


)


 

1


 


 

(9


)


 

30


 


 

(750


)


 

3.9


%


Gross profit


 

886


 


 

12


 


 

17


 


 

(17


)


 

898


 


 

(1.9


)%


SG&A


 

(520


)


 

(13


)


 

(7


)


 

(21


)


 

(561


)


 

(4.0


)%


Other operating income/(expenses)


 

17


 


 

(0


)


 

1


 


 

(8


)


 

9


 


 

(47.5


)%


Normalized EBIT


 

383


 


 

(1


)


 

11


 


 

(46


)


 

347


 


 

(11.9


)%


Normalized EBITDA


 

533


 


 

3


 


 

15


 


 

(58


)


 

493


 


 

(10.9


)%


Normalized EBITDA margin


 

32.2


%


 

29.9


%


 

(269)bps


 


   

Global Export and Holding Companies


 

2Q25


 

Scope


 

Currency

Translation


 

Organic

Growth


 

2Q26


 

Organic

Growth


Volumes


 

62


 


 

14


 


 

-


 


 

12


 


 

89


 


 

16.3


%


Revenue


 

144


 


 

2


 


 

1


 


 

97


 


 

244


 


 

66.1


%


Cost of sales


 

(168


)


 

(1


)


 

(4


)


 

(102


)


 

(275


)


 

(60.7


)%


Gross profit


 

(23


)


 

1


 


 

(3


)


 

(6


)


 

(32


)


 

(26.3


)%


SG&A


 

(368


)


 

(1


)


 

(6


)


 

6


 


 

(369


)


 

1.6


%


Other operating income/(expenses)


 

2


 


 

0


 


 

2


 


 

(0


)


 

3


 


 

(3.7


)%


Normalized EBIT


 

(389


)


 

(0


)


 

(7


)


 

(0


)


 

(397


)


 

(0.1


)%


Normalized EBITDA


 

(245


)


 

(23


)


 

(5


)


 

21


 


 

(252


)


 

7.9


%


Annex 2: Segment reporting (HY)


AB InBev Worldwide


 

HY25


 

Scope


 

Currency

Translation


 

Organic

Growth


 

HY26


 

Organic

Growth


Volumes


 

279 615


 


 

(1 489


)


 

-


 


 

2 286


 


 

280 412


 


 

0.8


%


Revenue


 

28 632


 


 

(106


)


 

1 783


 


 

1 618


 


 

31 927


 


 

5.7


%


Cost of sales


 

(12 602


)


 

72


 


 

(726


)


 

(446


)


 

(13 702


)


 

(3.6


)%


Gross profit


 

16 029


 


 

(34


)


 

1 058


 


 

1 173


 


 

18 225


 


 

7.4


%


SG&A


 

(8 812


)


 

(48


)


 

(486


)


 

(572


)


 

(9 917


)


 

(6.5


)%


Other operating income/(expenses)


 

383


 


 

(10


)


 

32


 


 

(35


)


 

369


 


 

(9.7


)%


Normalized EBIT


 

7 601


 


 

(92


)


 

603


 


 

566


 


 

8 677


 


 

7.6


%


Normalized EBITDA


 

10 156


 


 

(103


)


 

766


 


 

557


 


 

11 375


 


 

5.6


%


Normalized EBITDA margin


 

35.5


%


 

35.6


%


 

(5)bps


   

North America


 

HY25


 

Scope


 

Currency

Translation


 

Organic

Growth


 

HY26


 

 


Organic

Growth


Volumes


 

42 218


 


 

121


 


 

-


 


 

(779


)


 

41 561


 


 

(1.8


)%


Revenue


 

7 208


 


 

59


 


 

27


 


 

131


 


 

7 424


 


 

1.8


%


Cost of sales


 

(2 947


)


 

(7


)


 

(9


)


 

30


 


 

(2 932


)


 

1.0


%


Gross profit


 

4 261


 


 

53


 


 

18


 


 

161


 


 

4 492


 


 

3.8


%


SG&A


 

(2 174


)


 

(35


)


 

(10


)


 

(108


)


 

(2 328


)


 

(5.0


)%


Other operating income/(expenses)


 

23


 


 

(0


)


 

(1


)


 

(4


)


 

18


 


 

(18.5


)%


Normalized EBIT


 

2 110


 


 

18


 


 

7


 


 

48


 


 

2 183


 


 

2.3


%


Normalized EBITDA


 

2 459


 


 

25


 


 

8


 


 

14


 


 

2 505


 


 

0.6


%


Normalized EBITDA margin


 

34.1


%


 

33.7


%


 

(43)bps


   

Middle Americas


 

HY25


 

Scope


 

Currency

Translation


 

Organic

Growth


 

HY26


 

Organic

Growth


Volumes


 

73 903


 


 

(1 362


)


 

-


 


 

3 439


 


 

75 979


 


 

4.7


%


Revenue


 

8 124


 


 

(155


)


 

858


 


 

768


 


 

9 595


 


 

9.6


%


Cost of sales


 

(2 866


)


 

83


 


 

(283


)


 

(193


)


 

(3 259


)


 

(6.9


)%


Gross profit


 

5 258


 


 

(72


)


 

575


 


 

575


 


 

6 337


 


 

11.1


%


SG&A


 

(1 898


)


 

26


 


 

(201


)


 

(167


)


 

(2 241


)


 

(8.9


)%


Other operating income/(expenses)


 

14


 


 

0


 


 

(0


)


 

(22


)


 

(7


)


 

-


 


Normalized EBIT


 

3 374


 


 

(46


)


 

374


 


 

387


 


 

4 088


 


 

11.6


%


Normalized EBITDA


 

4 007


 


 

(44


)


 

435


 


 

369


 


 

4 767


 


 

9.3


%


Normalized EBITDA margin


 

49.3


%


 

49.7


%


 

(15)bps


   

South America


 

HY25


 

Scope


 

Currency

Translation


 

Organic

Growth


 

HY26


 

Organic

Growth


Volumes


 

75 089


 


 

-


 


 

-


 


 

341


 


 

75 430


 


 

0.5


%


Revenue


 

5 507


 


 

8


 


 

428


 


 

458


 


 

6 402


 


 

8.3


%


Cost of sales


 

(2 764


)


 

(17


)


 

(198


)


 

(140


)


 

(3 119


)


 

(5.1


)%


Gross profit


 

2 743


 


 

(9


)


 

230


 


 

318


 


 

3 282


 


 

11.6


%


SG&A


 

(1 712


)


 

(8


)


 

(114


)


 

(134


)


 

(1 968


)


 

(7.8


)%


Other operating income/(expenses)


 

201


 


 

(2


)


 

26


 


 

29


 


 

255


 


 

15.3


%


Normalized EBIT


 

1 233


 


 

(19


)


 

142


 


 

213


 


 

1 568


 


 

17.6


%


Normalized EBITDA


 

1 699


 


 

(9


)


 

174


 


 

212


 


 

2 076


 


 

12.5


%


Normalized EBITDA margin


 

30.9


%


 

32.4


%


 

120bps


EMEA


 

HY25


 

Scope


 

Currency

Translation


 

Organic

Growth


 

HY26


 

Organic

Growth


Volumes


 

44 924


 


 

(230


)


 

-


 


 

476


 


 

45 169


 


 

1.1


%


Revenue


 

4 454


 


 

(69


)


 

397


 


 

169


 


 

4 951


 


 

3.8


%


Cost of sales


 

(2 280


)


 

38


 


 

(202


)


 

(29


)


 

(2 473


)


 

(1.3


)%


Gross profit


 

2 174


 


 

(31


)


 

195


 


 

139


 


 

2 478


 


 

6.5


%


SG&A


 

(1 371


)


 

(11


)


 

(121


)


 

(78


)


 

(1 581


)


 

(5.7


)%


Other operating income/(expenses)


 

101


 


 

(8


)


 

4


 


 

(23


)


 

73


 


 

(25.1


)%


Normalized EBIT


 

904


 


 

(50


)


 

79


 


 

38


 


 

970


 


 

4.4


%


Normalized EBITDA


 

1 424


 


 

(41


)


 

127


 


 

37


 


 

1 546


 


 

2.7


%


Normalized EBITDA margin


 

32.0


%


 

31.2


%


 

(36)bps


   

Asia Pacific


 

HY25


 

Scope


 

Currency

Translation


 

Organic

Growth


 

HY26


 

 


Organic

Growth


Volumes


 

43 365


 


 

(39


)


 

-


 


 

(1 192


)


 

42 134


 


 

(2.8


)%


Revenue


 

3 108


 


 

10


 


 

70


 


 

(66


)


 

3 122


 


 

(2.1


)%


Cost of sales


 

(1 456


)


 

2


 


 

(28


)


 

41


 


 

(1 441


)


 

2.8


%


Gross profit


 

1 652


 


 

12


 


 

42


 


 

(25


)


 

1 681


 


 

(1.5


)%


SG&A


 

(941


)


 

(12


)


 

(20


)


 

(42


)


 

(1 015


)


 

(4.5


)%


Other operating income/(expenses)


 

41


 


 

(1


)


 

1


 


 

(14


)


 

27


 


 

(35.6


)%


Normalized EBIT


 

752


 


 

(1


)


 

24


 


 

(82


)


 

693


 


 

(10.9


)%


Normalized EBITDA


 

1 056


 


 

7


 


 

34


 


 

(107


)


 

990


 


 

(10.0


)%


Normalized EBITDA margin


 

34.0


%


 

31.7


%


 

(277)bps


   

Global Export and Holding Companies


 

HY25


 

Scope


 

Currency

Translation


 

Organic

Growth


 

HY26


 

Organic

Growth


Volumes


 

116


 


 

22


 


 

-


 


 

1


 


 

139


 


 

0.8


%


Revenue


 

231


 


 

40


 


 

3


 


 

159


 


 

433


 


 

68.0


%


Cost of sales


 

(290


)


 

(27


)


 

(6


)


 

(155


)


 

(477


)


 

(53.0


)%


Gross profit


 

(59


)


 

13


 


 

(3


)


 

4


 


 

(45


)


 

7.5


%


SG&A


 

(716


)


 

(7


)


 

(20


)


 

(42


)


 

(784


)


 

(5.8


)%


Other operating income/(expenses)


 

2


 


 

0


 


 

1


 


 

(0


)


 

3


 


 

(19.0


)%


Normalized EBIT


 

(773


)


 

7


 


 

(21


)


 

(38


)


 

(826


)


 

(4.9


)%


Normalized EBITDA


 

(489


)


 

(40


)


 

(11


)


 

32


 


 

(508


)


 

6.0


%


Annex 3: Consolidated statement of financial position


Million US dollar


 

31 December 2025


 

30 June 2026


.


   

ASSETS


   

Non-current assets


   

Property, plant and equipment


 

23 664


 

22 998


Goodwill


 

117 908


 

119 946


Intangible assets


 

41 985


 

42 274


Investments in associates


 

5 002


 

5 061


Investment securities


 

161


 

166


Deferred tax assets


 

2 708


 

2 766


Pensions and similar obligations


 

150


 

154


Income tax receivables


 

444


 

440


Derivatives


 

145


 

313


Trade and other receivables


 

1 871


 

2 026


Total non-current assets


 

194 039


 

196 143


 


   

Current assets


   

Investment securities


 

306


 

353


Inventories


 

5 107


 

5 528


Income tax receivables


 

785


 

622


Derivatives


 

583


 

629


Trade and other receivables


 

6 161


 

7 404


Cash and cash equivalents


 

11 638


 

7 658


Assets classified as held for sale


 

190


 

48


Total current assets


 

24 769


 

22 242


 


   

Total assets


 

218 808


 

218 385


 


   

EQUITY AND LIABILITIES


   

Equity


   

Issued capital


 

1 736


 

1 736


Share premium


 

17 620


 

17 620


Reserves


 

17 803


 

22 458


Retained earnings


 

50 128


 

51 686


Equity attributable to equity holders of AB InBev


 

87 287


 

93 500


 


   

Non-controlling interests


 

10 449


 

7 685


Total equity


 

97 736


 

101 185


 


   

Non-current liabilities


   

Interest-bearing loans and borrowings


 

72 128


 

68 908


Pensions and similar obligations


 

1 275


 

1 262


Deferred tax liabilities


 

11 400


 

11 565


Income tax payables


 

206


 

186


Derivatives


 

293


 

391


Trade and other payables


 

869


 

1 028


Provisions


 

425


 

384


Total non-current liabilities


 

86 596


 

83 724


 


   

Current liabilities


   

Bank overdrafts


 

14


 

29


Interest-bearing loans and borrowings


 

885


 

3 381


Income tax payables


 

1 825


 

1 235


Derivatives


 

6 104


 

4 021


Trade and other payables


 

25 455


 

24 605


Provisions


 

192


 

205


Total current liabilities


 

34 475


 

33 476


 


   

Total equity and liabilities


 

218 808


 

218 385


Annex 4: Consolidated statement of cash flows


For the six-month period ended 30 June


   

Million US dollar


 

2025


 

2026


   

OPERATING ACTIVITIES


   

Profit of the period


 

4 568


 


 

7 061


 


Depreciation, amortization and impairment


 

2 581


 


 

2 757


 


Net finance (income)/expense


 

1 678


 


 

74


 


Equity-settled share-based payment expense


 

309


 


 

270


 


Income tax expense


 

1 404


 


 

1 704


 


Share of results of associates


 

(144


)


 

(148


)


Other non-cash items


 

(93


)


 

(199


)


Cash flow from operating activities before changes in working capital and use of provisions


 

10 304


 


 

11 520


 


Decrease/(increase) in trade and other receivables


 

(1 130


)


 

(1 077


)


Decrease/(increase) in inventories


 

(242


)


 

(370


)


Increase/(decrease) in trade and other payables


 

(2 284


)


 

(909


)


Pension contributions and use of provisions


 

(278


)


 

(158


)


Cash generated from operations


 

6 370


 


 

9 007


 


Interest paid


 

(1 916


)


 

(1 910


)


Interest received


 

241


 


 

243


 


Dividends received


 

135


 


 

101


 


Income tax paid


 

(2 126


)


 

(2 200


)


Cash flow from/(used in) operating activities


 

2 704


 


 

5 241


 


   

INVESTING ACTIVITIES


   

Acquisition of property, plant and equipment and of intangible assets


 

(1 404


)


 

(1 406


)


Proceeds from sale of property, plant and equipment and of intangible assets


 

55


 


 

46


 


Sale/(acquisition) and others related to subsidiaries, net of cash


 

(4


)


 

(757


)


Proceeds from sale/(acquisition) of other assets


 

47


 


 

310


 


Cash flow from/(used in) investing activities


 

(1 306


)


 

(1 807


)


   

FINANCING ACTIVITIES


   

Proceeds from borrowings


 

4 067


 


 

555


 


Repayments of borrowings


 

(3 998


)


 

(309


)


Dividends paid


 

(3 147


)


 

(2 596


)


Share buyback


 

(1 901


)


 

(1 301


)


Payment of lease liabilities


 

(354


)


 

(364


)


Derivative financial instruments


 

114


 


 

(319


)


Sale/(acquisition) of non-controlling interests


 

(314


)


 

(3 389


)


Other financing cash flows


 

(303


)


 

219


 


Cash flow from/(used in) financing activities


 

(5 837


)


 

(7 505


)


   

Net increase/(decrease) in cash and cash equivalents


 

(4 438


)


 

(4 071


)


Cash and cash equivalents less bank overdrafts at beginning of year


 

11 174


 


 

11 623


 


Effect of exchange rate fluctuations


 

410


 


 

76


 


Cash and cash equivalents less bank overdrafts at end of period


 

7 146


 


 

7 629


 


 


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260729033132/en/



Permalink

https://www.aetoswire.com/en/news/3007202656528


Contacts

Investors

Shaun Fullalove

E-mail: shaun.fullalove@ab-inbev.com


Ekaterina Baillie

E-mail: ekaterina.baillie@ab-inbev.com


Patrick Ryan

E-mail: patrick.ryan@ab-inbev.com


Media

Media Relations

E-mail: media.relations@ab-inbev.com